Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) insider William Banyai sold 798 shares of Twist Bioscience stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total transaction of $29,629.74. Following the completion of the transaction, the insider now owns 345,188 shares in the company, valued at $12,816,830.44. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
William Banyai also recently made the following trade(s):
- On Tuesday, April 2nd, William Banyai sold 327 shares of Twist Bioscience stock. The stock was sold at an average price of $32.74, for a total transaction of $10,705.98.
Twist Bioscience Price Performance
Shares of NASDAQ TWST opened at $43.13 on Wednesday. Twist Bioscience Co. has a 12-month low of $11.81 and a 12-month high of $44.92. The company has a market capitalization of $2.51 billion, a PE ratio of -12.84 and a beta of 1.64. The firm's 50-day moving average is $34.15 and its two-hundred day moving average is $31.52.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, topping analysts' consensus estimates of ($0.84) by $0.05. The company had revenue of $75.30 million during the quarter, compared to analysts' expectations of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The business's revenue for the quarter was up 25.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.06) earnings per share. On average, analysts forecast that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.
Institutional Investors Weigh In On Twist Bioscience
Shocking $16T Elon Musk Crypto Leak
From Crypto 101 Media | Ad
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market.
Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account."
Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Click here now to get your copy.
Several hedge funds have recently modified their holdings of the company. Federated Hermes Inc. purchased a new position in shares of Twist Bioscience during the third quarter valued at approximately $29,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Twist Bioscience by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company's stock worth $30,000 after purchasing an additional 721 shares during the period. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience during the fourth quarter worth $30,000. Allspring Global Investments Holdings LLC grew its position in shares of Twist Bioscience by 51.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company's stock valued at $70,000 after purchasing an additional 1,179 shares during the period. Finally, Headlands Technologies LLC acquired a new position in Twist Bioscience in the first quarter valued at $124,000.
Analyst Ratings Changes
TWST has been the subject of several analyst reports. Evercore ISI increased their price target on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an "outperform" rating in a report on Friday, May 3rd. Scotiabank raised their price target on Twist Bioscience from $43.00 to $48.00 and gave the company a "sector outperform" rating in a report on Monday. The Goldman Sachs Group raised Twist Bioscience from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $25.00 to $45.00 in a report on Wednesday, January 17th. Barclays boosted their target price on shares of Twist Bioscience from $40.00 to $45.00 and gave the stock an "overweight" rating in a research report on Friday, May 3rd. Finally, Robert W. Baird increased their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the company an "outperform" rating in a report on Friday, May 3rd. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $42.50.
Read Our Latest Report on TWST
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
